Management of Breakthrough Bleeding on Hormonal Contraception

Initial Management Approach

The Centers for Disease Control and Prevention recommends ruling out pregnancy, sexually transmitted infections, and structural lesions before initiating treatment for breakthrough bleeding 2, 3
The American College of Obstetricians and Gynecologists suggests assessing current medications that may interfere with contraceptive efficacy 2

The Centers for Disease Control and Prevention recommends NSAIDs for 5-7 days during bleeding episodes as first-line treatment for breakthrough bleeding 1, 2, 3
The American College of Obstetricians and Gynecologists suggests using celecoxib 200 mg daily or mefenamic acid 500 mg three times daily for significant cessation of bleeding within 7 days 2

For combined hormonal contraceptive users, the Centers for Disease Control and Prevention recommends NSAIDs for 5-7 days during bleeding episodes and considering a hormone-free interval for 3-4 consecutive days for heavy or prolonged bleeding 1, 3
For IUD users, the Centers for Disease Control and Prevention suggests NSAIDs for 5-7 days during bleeding episodes and hormonal treatment with COCs or estrogen for 10-20 days 1, 3
For implant users, the Centers for Disease Control and Prevention recommends NSAIDs for 5-7 days during bleeding episodes and hormonal treatment with low-dose COCs or estrogen for 10-20 days 1, 2

The American College of Obstetricians and Gynecologists advises against dismissing bleeding without ruling out pregnancy, infection, or structural pathology 2, 3
The Centers for Disease Control and Prevention recommends against recommending hormone-free intervals during the first 21 days of extended/continuous CHC regimens 1, 3

The Centers for Disease Control and Prevention suggests no routine follow-up visit is required for contraceptive users, but advises women to return at any time to discuss side effects or concerns 1, 2
The American College of Obstetricians and Gynecologists recommends re-evaluating for underlying gynecological problems if bleeding persists beyond initial months 3